CPP
FOMX

Crow Point Partners’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Crow Point Partners’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$341K Buy
103,816
+16,343
+19% +$52K 0.53% 40
2019
Q3 		$269K Buy
87,473
+49,053
+128% +$138K 0.04% 94
2019
Q2 		$91K Buy
+38,420
New +$115K 0.01% 121

Other funds holding FOMX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Crow Point Partners's FOMX Position: Q4 2019 in Review

Crow Point Partners increased its Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) stake by 19% in Q4 2019, buying an estimated $52K and bringing the position to 103,816 shares worth $341K. The position accounts for 0.53% of the portfolio, ranked #40.

Crow Point Partners first reported a position in FOMX in Q2 2019 and has held it in 3 quarters since. 65 funds tracked by Wall St. Rank hold FOMX as of Q4 2019.

  • Crow Point Partners held 103,816 shares of Foamix Pharmaceuticals Ltd. Ordinary Shares worth $341K as of Q4 2019.
  • Crow Point Partners bought 16,343 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q4 2019, an estimated $52K.
  • Foamix Pharmaceuticals Ltd. Ordinary Shares made up 0.53% of Crow Point Partners's portfolio in Q4 2019, its #40 holding.
  • Crow Point Partners first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2019 and has held it in 3 quarters since.
  • 65 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.